Carl  Figdor

Carl  Figdor

Figdor, Carl

Member management team



Research interests include immunology and cell biology, with a specific focus on the molecular mechanisms controlling antigen presenting cells, in particular dendritic cells. Major current projects include an investigation of the role of lectin-like receptors in antigen uptake and the role of the cytoskeleton in dendritic cell adhesion and migration. The use of high resolution single cell imaging tools to achieve greater insights into the topography of cell surface receptors and the advancement of translational medicine through the treatment of cancer patients using antigen loaded dendritic cell vaccines are among his current fascinations as an immunologist.

Short CV

Carl Figdor obtained his Masters degree in 1979 from the University of Utrecht and his PhD degree in 1982 from the University of Amsterdam working at the Netherlands cancer Institute, where he got tenured in 1985 and started his own research group on tumor immunology. In 1992 Carl Figdor became professor in Cell Biophysics at the University of Twente (until 2009), and in 1994 he moved to the UMC st Radboud to start a new department on Tumor Immunology as a professor in immunology. Here he initiated a large translational program exploiting the immune system to fight cancer. From  2001 - 2010 he served as the first scientific director of the Nijmegen Centre for Molecular Life Sciences (NCMLS), in which also his department is located. Carl Figdor has been a member of the Royal Netherlands Academy of Arts and Sciences since 2008 and is the recipient of several awards, including the Dutch van Loghum award for Immunology in 1999, the Dutch Spinoza Award in 2006, and the KWO award from the Dutch Cancer Society in 2009. He obtained an ERC Advanced Investigator grant in 2011 and 2019.

Breakthrough discoveries

  1. Finding that the leukocyte integrin LFA-1 has different conformations and needs to be activated for stable binding to its ligand ICAM-1, Nature 1989
  2. Discovery of the C-type lectin receptor DC-SIGN as a major pathogen receptor and adhesion receptor, Cell 2000
  3. Application of MRI and scintigraphy to follow the migratory behavior of  dendritic cell in vivo in patients, Nature Biotechnology

Key publications

  1. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood, 2011. 118(15): 4111-9 2011.
  2. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials, 2011. 32(28): 6791-803.
  3. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res, 2011. 17(17): 5725-35.
  4. Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, Figdor CG. Imaging of cellular therapies. Adv Drug Deliv Rev, 2010. 62(11): 1080-93.
  5. Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010. 116(4): 564-74.